Company Overview and News
In our REIT Lab we cover most all commercial mortgage REITs, and the sector can be further broken down into two categories: pure balance sheet lender and balance sheet/conduit lender.
BXMT LADR TRTX 511505 CAPITALT STWD ACRE STWD.WI
2018-08-10 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 TRTX
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-226642 CALCULATION OF REGISTR
424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-226642 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offe
Shares of CBRE Group Inc. (CBRE - Free Report) have gained 6.3% in the past three months compared with its industry’s growth of 5.2%. Further, the trend in current-year earnings estimate revisions indicates a solid outlook for the company. The fundamentals appear solid for this Zacks Rank #2 (Buy) stock and there are enough scope for its price appreciation in the near term. In fact, CBRE Group has a robust scale as the largest commercial real estate services and investment firm (based on 2017 revenues).
CBG TRTX CIG MMI CIGI CBRE
The following slide deck was published by TPG RE Finance Trust in conjunction with their 2018 Q2 earnings call.
TPG RE Finance Trust (TRTX - Free Report) just came out with quarterly earnings of $0.44 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.
APLE AMT TRTX TCMD GTLS BWXT
trtx-8k_20180806.htm UNITED STATES
trtx-10q_20180630.htm UNITED STATES
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
ECOR PLNT PKG AEP NINE ADT GE COF-P GILD TMUS PDYPF SYF XERS JNJ VZ MSFT ADS KZR NNN EIDX FB AVRO HOPE NFLX AXP EHC BAC COF-D SEAS COF-C COF-F KR KS IIIV PNFP AAPL DDOC SJM INPAP SIX JPM GNE WRK LGEJY KMRFZ DE 39IB KMX RF UAL WMT CFIN LGEAF IP AMZN MGTA NTRS HON KMI CIWV HCSG KMR CVB VLKAY LGEIY EBAY EPRT STT SLB BAC DFS LGEPF STM BBY BX BK STM LTXB LGLD SLB FOXA CLW PM NTRSP AUTL DLPH SWKS GS SWK TRTX GM PII DIS NEE IBM MOR F GEC C CMCSA COF FUN FUL CFG HBAN XEL TGT BLK S PPG T SNE DPZ
2018-07-13 bloomberg - 1
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
XKE BPY VNO VNO.WI VNORP CXP TRTX NYRT
The July 2018 REML dividend will bring, on a monthly compounded annualized rate, its yield to 22.2%.
SLDA STAR ANH ORC MITT BAC REM LADR TRTX CMO KREF AGNC RWT GPMT ABR GE GEC CEFL HOG ARR XAN SLD GNE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET